This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What's in the Offing for LabCorp's (LH) Earnings in Q4?
by Zacks Equity Research
With near-term visibility seeming bleak at the moment, we anticipate PAMA to once again dent LabCorp's (LH) fourth-quarter top line.
What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?
by Zacks Equity Research
Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.
Is a Beat in the Cards for Humana's (HUM) Earnings in Q4?
by Zacks Equity Research
Humana's (HUM) fourth-quarter results are likely to reflect lower membership, partly offset by higher revenues.
The Zacks Analyst Blog Highlights: Agilysys, Tandem Diabetes Care, Enphase Energy, Forterra and MagnaChip Semiconductor
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Agilysys, Tandem Diabetes Care, Enphase Energy, Forterra and MagnaChip Semiconductor
5 Top-Ranked Growth Stocks for February That Have Jumped YTD
by Nalak Das
Several positive factors have strengthened investors' confidence in risky assets like equities. A few top-ranked growth stocks surged in January and still have strong upside left.
Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?
by Zacks Equity Research
Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.
What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?
by Zacks Equity Research
Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.
Zacks.com featured highlights include: Synaptics, MagnaChip Semiconductor, Tandem Diabetes Care and International Money Express
by Zacks Equity Research
Zacks.com featured highlights include: Synaptics, MagnaChip Semiconductor, Tandem Diabetes Care and International Money Express
Moving Average Crossover Alert: Tandem Diabetes Care
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Check 4 Best Liquid Bets to Power Your Portfolio
by Zacks Equity Research
Four top-ranked liquid stocks that investors can bank on for fat returns.
What's in Store for Thermo Fisher (TMO) in Q4 Earnings?
by Zacks Equity Research
Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.
Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?
by Zacks Equity Research
Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?
by Zacks Equity Research
Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.
Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.
Moving Average Crossover Alert: Tandem Diabetes Care
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?
by Zacks Equity Research
Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.
Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?
by Zacks Equity Research
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.
Diabetes Management Gains FDA Attention: 3 Stocks in Focus
by Sriparna Ghosal
The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.
Strong Pipeline Aids Tandem Diabetes Despite Stiff Rivalry
by Zacks Equity Research
Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.
6 MedTech Stocks That are Set to Beat the Market in 2020
by Trina Mukherjee
Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.
Tandem Diabetes Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Tandem Diabetes Care has been struggling lately, but the selling pressure may be coming to an end soon.
Tandem Diabetes Gets FDA Nod for t:slim X2 Insulin Pump
by Zacks Equity Research
The FDA nod for Tandem Diabetes' (TNDM) t:slim X2 insulin pump with Control-IQ will speed up its pump shipments within the United States and grow its clientele.
Digital Diabetes Management Gains Momentum: 3 Stocks in Focus
by Trina Mukherjee
With digital diabetes management space rapidly gaining momentum, patients with diabetes can look forward to better and improved outcomes.
Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
by Zacks Equity Research
Investor confidence in Tandem Diabetes (TNDM) stock is at a high, thanks to solid prospects.
Will Tandem Diabetes Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Tandem Diabetes Care.